Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Investigator-Initiated Clinical Trial Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of CS01 in Patients With Locally Advanced or Metastatic Solid Tumors.

NCT07461181 is registered in ClinicalTrials.gov with Ruijin Hospital as lead sponsor.

NCT NCT07461181
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07461181 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Investigator-Initiated Clinical Trial Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of CS01 in Patients With Locally Advanced or Metastatic Solid Tumors.
Lead sponsor
Ruijin Hospital
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
December 30, 2024
Completion date
December 31, 2026
Enrollment
10 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

locally advanced or metastatic solid tumors